Advertisement
Advertisement
PMCB
PharmaCyte Biotech, Inc. Common Stock
0.53
USDSponsored
-0.01
-1.50%
Aug 24, 15:59 UTC -4
Closed
After-Market
0.52
-0.01
-0.95%
PMCB Earnings Reports
Positive Surprise Ratio
PMCB beat 2 of 4 last estimates.
50%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q4 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
PharmaCyte Biotech, Inc. Common Stock earnings per share and revenue
On Aug 10, 2026, PMCB reported earnings of -- USD per share (EPS) for Q4 26, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Karyopharm Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.30
Actual
-$2.31
Surprise
-78.16%
Vyome Holdings, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.10
Surprise
+48.40%
CDT Equity Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-Actual
-$8.71
Surprise
-
Nektar Therapeutics
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$2.02
Actual
-$1.23
Surprise
+39.24%
Altimmune, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+14.22%
Aquestive Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.18
Surprise
-70.78%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.50
Actual
-$0.63
Surprise
-25.40%
Journey Medical Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.01
Surprise
+56.33%
MediWound Ltd.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.77
Actual
-$0.77
Surprise
+0.89%
PolyPid Ltd. Ordinary Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.35
Surprise
+9.28%
FAQ
What were PharmaCyte Biotech, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2026?
For Q4 2026, PharmaCyte Biotech, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to PharmaCyte Biotech, Inc. Common Stock's Q4 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is PharmaCyte Biotech, Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for PharmaCyte Biotech, Inc. Common Stock's next earnings report?
Based on --
analysts, PharmaCyte Biotech, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement